ImmunoCellular Therapeutics, Ltd. (IMUC)

0.1979 0.0000 (0.00%) At close: 11:08AM EDT

ImmunoCellular Therapeutics, Ltd.

136 Summit Avenue
Montvale, NJ 07645
United States
201 351 0605
https://www.eompharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 3

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Irach B. Taraporewala B.S., M.S., Ph.D.	CEO, President & Director	265.65k	N/A	1956
Mr. Wayne I. Danson CPA	CFO & Treasurer	150k	N/A	1954
Mr. Eli Goldberger	Founder, Chairman & COO	N/A	N/A	1990
Dr. Shalom Z. Hirschman M.D.	Co-Founder, Chief Scientific Officer & Medical Director	N/A	N/A	1936

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.

Corporate governance

ImmunoCellular Therapeutics, Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.